key: cord-0688451-u44usea7
authors: Townsend, A.; Rijal, P.; Xiao, J.; Tan, T. K.; Huang, K.-Y. A.; Schimanski, L.; Ho, J.; Gupta, N.; Rahikainen, R.; Matthews, P. C.; Crook, D.; Hoosdally, S.; Street, T.; Rudkin, J.; Stoesser, N.; Karpe, F.; Neville, M.; Ploeg, R.; Oliveira, M.; Roberts, D. J.; Lamikanra, A. A.; Tsang, H. P.; Bown, A.; Vipond, R.; Mentzer, A. J.; Knight, J. C.; Kwok, A.; Screaton, G.; Mongkolsapaya, J.; Dejnirattisai, W.; Supasa, P.; Klenerman, P.; Dold, C.; Baillie, K.; Moore, S. C.; Openshaw, P. J.; Semple, M. G.; Turtle, L. C.; Ainsworth, M.; Allcock, A.; Beer, S.; Bibi, S.; Clutterbuck, E.; Espinosa, A.; Me,
title: A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
date: 2020-10-06
journal: nan
DOI: 10.1101/2020.10.02.20205831
sha: d2b7ab2dd99a3aeece9853514b052385ef6b521d
doc_id: 688451
cord_uid: u44usea7

Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of seroconversion in populations, detection of seroconversion after vaccination, and for seeking evidence for a level of antibody that may be protective against COVID-19 disease. Several high-performance commercial tests have been described, but these require centralised laboratory facilities that are comparatively expensive, and therefore not available universally. Red cell agglutination tests have a long history in blood typing, and general serology through linkage of reporter molecules to the red cell surface. They do not require special equipment, are read by eye, have short development times, low cost and can be applied as a Point of Care Test (POCT). We describe a red cell agglutination test for the detection of antibodies to the SARS-CoV-2 receptor binding domain (RBD). We show that the Haemagglutination Test (HAT) has a sensitivity of 90% and specificity of 99% for detection of antibodies after a PCR diagnosed infection. The HAT can be titrated, detects rising titres in the first five days of hospital admission, correlates well with a commercial test that detects antibodies to the RBD, and can be applied as a point of care test. The developing reagent is composed of a previously described nanobody to a conserved glycophorin A epitope on red cells, linked to the RBD from SARS-CoV-2. It can be lyophilised for ease of shipping. We have scaled up production of this reagent to one gram, which is sufficient for ten million tests, at a cost of ~0.27 UK pence per test well. Aliquots of this reagent are ready to be supplied to qualified groups anywhere in the world that need to detect antibodies to SARS-CoV-2, but do not have the facilities for high throughput commercial tests.

Red cell agglutination tests have a distinguished history. Since Landsteiner's classic 93 observations in 1901 (Landsteiner, 1961 ) (English translation), they have been used for the 94 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.02.20205831 doi: medRxiv preprint determination of blood groups (Schwarz & Dorner, 2003) detection of influenza viruses (Hirst, 95 1941) and in a wide variety of applications championed by Prof. Robin Coombs for the 96 detection of specific antibodies or antigens (Coombs, Mourant, & Race, 1945 ) (reviewed by 97 (Pamphilon & Scott, 2007) ). They have the great advantage of being simple, inexpensive, can 98 be read by eye, and do not require sophisticated technology for their application. In the 99 recent era the linkage of an antigen to the red cell surface has become easier with the 100 possibility of fusing a protein antigen sequence with that of a single domain antibody or 101 nanobody specific for a molecule on the red cell surface (discussed in (Habib et al., 2013) ). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.02.20205831 doi: medRxiv preprint

The IH4-RBD sequence ( Figure 1B ) was codon optimised and expressed in Expi293F cells in a 145 standard expression vector (available on request). One advantage of this mode of production 146 compared to bacterially produced protein as used by Habib et al, is that the reagent will carry 147 the glycosylation moieties found in humans, which may play a role in the antigenicity of the 148 RBD (Pinto et al., 2020). The protein (with a 6xHis tag at the C-terminus for purification) was 149 purified by Ni-NTA chromatography which yielded ~160 mg/L. We later had one gram of the 150 protein synthesised commercially by Absolute Antibody, Oxford. The IH4-RBD protein ran as 151 single band at ~40 kDa on SDS PAGE ( Figure 1C) . 152 153

One purpose envisaged for the HAT is for use as an inexpensive Point of Care Test for 155 detection of antibodies in capillary blood samples obtained by a "finger-prick". We therefore 156 wished to employ human red cells as indicators without the need for cell separation or 157 washes, to mimic this setting. The use of V-bottom microtiter plates to perform simplified 158 hemagglutination tests was first described over 50 years ago (Wegmann & Smithies, 1966) . 159

In preliminary tests, we observed that 50 µL of whole blood (K2EDTA sample) diluted 1:40 in 160 phosphate-buffered saline (PBS), placed in V-bottomed wells of a standard 96-well plate, 161 settled in one hour to form a button of red cells at the bottom of the well. The normal 162 haematocrit of blood is ~40% vol/vol, so this dilution provides ~1% red cells. If the plate was 163 then tilted, the red cell button flowed to form a "teardrop" in ~30 seconds (for example Figure  164 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 6, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 6, 2020. In summary, these results showed that all of the known epitopes bound by characterised 227 monoclonal antibodies were displayed by the IH4-RBD reagent, as well as the ACE2 binding 228 site, and could mediate agglutination by specific antibodies, divalent nanobodies, or ACE2-Fc. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 6, 2020. shows that the HAT titre matched the RBD ELISA results. Four samples were scored as 244

negative in both assays. The remaining results showed that in general the HAT titre increased 245 with the ELISA end point titre. One sample gave a positive titre of 1:320 in the HAT but was 246 negative in ELISA (indicated with an arrow). We investigated this sample with a developer 247 composed of the IH4 nanobody without the RBD component, which revealed that 248 agglutination was RBD dependent (not shown). This sample was also positive at 1:1123 in an 249 ELISA for full length spike protein (not shown). The highest titre detected in these samples by 250 the HAT was 1:1280 ( Figure 3B ). 251

These preliminary results showed that the HAT could detect antibodies to the RBD in plasma 253 samples from convalescent patients in a similar manner to an ELISA test, but were not 254 sufficient to establish the sensitivity and specificity of the HAT. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.02.20205831 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.02.20205831 doi: medRxiv preprint negative. These rules were established before setting up the tests. Disagreements (7% 279 overall) were resolved by accepting the weaker interpretation -i.e. if one observer scored 280 positive but the other negative, the well was scored as negative. Having completed the 281 scoring the columns of samples were re-randomised and the test and scoring repeated. With these rules in place we obtained in the first run sensitivity 88%, specificity 99%, and in 290 the second run sensitivity 93%, specificity 99% ( Figure 4 ). The Siemens Atellica 291

Chemiluminescence assay for detection of IgG antibodies to the RBD was run in parallel on 292 293 of these 297 samples and gave sensitivity 100%, specificity 100% for this sample set. 293

We decided prior to this formal assessment to score wells with partial teardrop formation as 295 negative, as these wells tended to give rise to disagreements between scorers and were not 296 very helpful. Fifteen of 297 wells gave a partial teardrop. Six of these fifteen were from PCR-297 ve donors and scored negative on the Siemens assay, 9/16 were from PCR+ve donors and 298

were Siemens positive. If partial teardrops were scored as positive, the sensitivity of the two 299 assays increased to 97% and 99% (from 88% and 93%), but specificity was reduced to 96% 300 and 98% (from 99%). This small loss of specificity would be unacceptable in sero-surveys 301

where the expected prevalence of previous SARS-CoV-2 infection was low. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 6, 2020. . https://doi.org/10.1101/2020.10.02.20205831 doi: medRxiv preprint to the RBD (P <0.0001; two-tailed Fisher's exact test, Figure 5B ). Fifty-four of the 153 samples 344

were from 25 donors with COVID-19 from whom repeated samples were taken on days 1, 3, 345 or 5 of admission. The HAT detected a rise in agglutination titre over the first five days of 

The HAT is designed to detect antibodies to the RBD starting at a serum dilution of 1:40, and 400

we have found that that 50 µL of 1:40 dilution of whole blood provides an optimal 401 concentration of red blood cells for detection by agglutination in V-bottomed 96 well plates. 402

We have not completed an extensive analysis of the HAT as a Point of Care Test. However, 403

we have preliminary evidence that lyophilised IH4-RBD sent to the National Institute of 404 Immunology, New Delhi, functions as a Point of Care Test on capillary blood obtained by 405 finger-prick. In Figure 6 , three positive (donors 1, 2 and 3) and three negative (donors 4, 5 and 406 6) HAT results are compared to a standard ELISA for detection of antibodies to the RBD. 407 The sensitivity of the single point HAT can be enhanced (to ~98%) if wells with partial teardrop 462 formation are scored as positive. However, this improvement in sensitivity is gained at the the spot test at 1:40, we recommend obtaining confirmation for these by ELISA. Improvement 465 in the operating characteristics of the HAT may be possible by a systematic analysis of buffer 466 composition and experimental conditions, and is being investigated. We have deliberately 467 kept complexity to a minimum, and thus all dilutions were made in standard PBS, and for the 468 moment we recommend scoring wells with partial teardrop formation as negative. 469

It is interesting that the HAT titrations actually performed a little better than the Siemens test 471 on 153 stored plasma samples from donors during the first five days of their hospital 472 admission (note that symptom onset may have been several days earlier), in whom it 473 detected 86% (81% in the repeat) of samples from PCR-diagnosed donors, compared to 74% 474 for the Siemens test, and gave 100% specificity for the sample set containing control plasma 475 from patients with sepsis and healthy controls. We speculate that at this early period of the 476 COVID-19 illness the immune response may be dominated by IgM that would be expected to 477 be particularly efficient at crosslinking the IH4-RBD labelled red cells. In addition, of the 478 twenty-five donors who were tested more than once in the first five days in hospital, the HAT 479 detected a rise in titre in seventeen (68%). A fixed high titre was detected in a further five to 480 provide a sensitivity of 88% in these twenty-five cases. In situations of high clinical suspicion, 481 the HAT could potentially have a place as a helpful test to support the diagnosis of COVID-19 482 by detecting a rising titre of antibodies to the RBD during hospital admission. In patients with 483 a prior probability of a diagnosis of COVID-19 of ~10%, the likelihood ratio of ~175 for the HAT 484 provides a posterior probability of ~95% for this diagnosis. However, it is essential that if 485 clinicians use a rising titre in the HAT as a diagnostic aid, they should be aware of the relatively 486 low sensitivity (~68%) in this context. 487

With a specificity of 99%, the HAT could be employed for epidemiological surveys of the 489 seropositive rate in stored serum/plasma samples from populations with a moderate 490 expected prevalence ~10%, which would entail a negative predictive value of ~90%. The HAT 491 may be useful to detect seroconversion after vaccination, and for the identification of 492 potential donors of high titre plasma for therapy, if the clinical trials that are in progress 493 demonstrate a benefit. In the absence of knowledge about the level of antibody that indicates 494 protection, the HAT should not be used to provide personal results to individuals, as discussed agenda/COVID-19-testing-a-national-strategy.html). Finally, we show that the lyophilised 497 IH4-RBD reagent sent to New Delhi functioned as expected in preliminary point of care testing 498 on capillary samples obtained by finger-prick. However, additional evidence is needed to 499

show that the sensitivity and specificity of the HAT, applied as a Point of Care Test in this way, 500 are comparable to the tests on stored plasma samples, as stressed by the IDSA guideline on 501 serological testing (Hanson et al., 2020) . This will need to be done in field conditions, which is 502 planned. 503

The technique required for applying the HAT can be learned in a day by a trained laboratory 505 technician, paramedic, nurse or doctor. We have produced one gram of the developing IH4-506 RBD reagent (enough for ten million test wells) and offer to ship lyophilised aliquots of this 507 material (sufficient for 10,000 tests) anywhere in the world, free of charge, for use as a 508

research reagent for serological studies of COVID-19. temperature for 1 hour. After incubation, plates were washed, and anti-human IgG 593 conjugated with Horseradish Peroxidase (HRP) (Southern Biotech) was added in each well. 594

After 1 h incubation, plates were washed and developed by OPD-substrate (Sigma-Aldrich) in 595 dark at room temperature. The reaction was stopped using 2N HCl and the optical density 596 (OD) was measured at 492 nm. The RBD-antigen coated wells that were added with sample 597 diluent alone were used as the blank. The OD values from sample wells were plotted after 598 subtracting the mean of OD values obtained in the blank wells. • IH4-RBD Reagent diluted 2 µg/mL in PBS. This remains active for at least 1-2 weeks 612 stored at 4 °C 613

• V-bottomed 96-well plates, numbered, dated, timed (helps when timing many plates) 614

• Positive control monoclonal antibody CR3022 diluted to 2 µg/mL in PBS 615 616

Monoclonal antibody to human IgG (Gamma chain specific) Clone GG-5 Sigma Cat. No. I5885 618 2. Add 50 µL 1:20 O-ve blood collected in (so that now sample is diluted to 1:40 and red 623

3. Mix and transfer 50/100 µL to neighbouring columns 2,4,6,8,10,12 for -ve controls. 625

The negative control is important because in rare cases, particularly in donors who 626

have received blood transfusions, the sample in principle may contain antibodies to 627 non-ABO or Rhesus D antigens. 628 4. Add 50 µL IH4-RBD reagent (2 µg/mL in PBS = 100 ng/well) to Columns 1,3,5,7,9,11 629 5. Add 50 µL PBS to columns 2,4,6,8,10,12. GGCCAGCGGCTACACCGATAGCACATACTGCGTCGGCTGGTTCAGACAGGCCCCTGGCAAAG  AGAGAGAGGGCGTCGCCAGAATCAACACCATCAGCGGCAGACCTTGGTACGCCGACTCTGTG  AAGGGCAGATTCACAATCAGCCAGGACAACAGCAAGAACACCGTGTTTCTGCAGATGAACA  GCCTGAAGCCAGAGGACACCGCCATCTACTACTGCACCCTGACCACCGCCAACAGCAGAGGC  TTTTGTTCCGGCGGCTACAACTACAAAGGCCAGGGCACCCAAGTGACCGTGTCTAGCGCGTC  GACCGGCTCTGGCGGCAGCGGCAACATCACCAATCTGTGCCCTTTCGGCGAGGTGTTCAACG  CCACCAGATTTGCCAGCGTGTACGCCTGGAACCGGAAGAGAATCAGCAACTGCGTGGCCGAC  TACAGCGTGCTGTACAATAGCGCCAGCTTCAGCACCTTCAAGTGCTACGGCGTGTCCCCTACC  AAGCTGAACGACCTGTGCTTCACCAATGTGTACGCCGACAGCTTCGTGATCAGAGGCGACGA  AGTTCGGCAGATCGCTCCTGGACAGACAGGCAAGATCGCCGATTACAACTACAAGCTGCCCG  ACGACTTCACCGGCTGCGTGATCGCCTGGAATAGCAACAACCTGGACAGCAAAGTCGGCGGC  AACTACAACTACCTGTACCGGCTGTTCCGGAAGTCCAACCTGAAGCCTTTCGAGCGGGACAT  CAGCACCGAGATCTATCAGGCCGGCAGCACCCCTTGTAATGGCGTGGAAGGCTTCAACTGCT  ACTTCCCACTGCAGTCCTACGGCTTTCAGCCTACAAACGGCGTGGGCTACCAGCCTTATAGAG  TGGTGGTGCTGAGCTTCGAACTGCTGCATGCCCCTGCTACCGTGTGCGGCCCTAAAAAACACC  ATCACCACCACCATTGA 

ACE2-Fc has been described

Preparation: Clean Hands, warm digit. Prepare a plate (96-well V-bottomed) labelled 657 with Date and Time

Prick skin on outer finger pulp with disposable, single use BD or another Lancet

20 µL pipette, mix immediately into 20 µL K2EDTA 662 (3.6 mg/mL/PBS) in Eppendorf. If possible, take 20 µL of blood and mix into 80 µL 663 K2EDTA solution. Another approach is collection of blood drops into a BD Microtainer

K2E EDTA lavender vials that take 250-500 µL

for 20 µL sample dilute to 666 800 µL (add 700 µL PBS)

NC, negative control) -see figure 6

Add 10 µL of control anti RBD Mab CR3022 (2 µg/mL stock in PBS, 20 ng/well)

Add 50 µL IH4-RBD (2 µg/mL in PBS) to "T" (Test) and "+ve" wells, 50 µL PBS to "-ve

Incubate 1 hour at RT for Red Cells to form a pellet in the "-ve" well Absence of the IH4 epitope should be very rare

The red cells can be removed and a preparation of 1:40 O-691 ve red cells used as above to titrate the sample. In principle the autologous red cells 692 could be washed repeatedly, resuspended in the same volume of PBS, and used as 693 indicators for the titration, however we have not attempted to do this

is funded by the Medical Research Council (MR/P021336/1)

Charitable Trust (charity number 1011770) and the Chinese Academy of Medical Sciences 724 (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no

is funded by the Wellcome Trust (grant ref 110110Z/15/Z)

is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z)

The Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2

Recombinant from HEK293 Cells, NR-52306 was produced under 734 HHSN272201400008C and obtained through BEI Resources

A serological assay to detect SARS-CoV-2 seroconversion in 752 humans

Structures of Human Antibodies Bound to SARS-CoV

Spike Reveal Common Epitopes and Recurrent Features of Antibodies

A new test for the detection of weak and 758 incomplete Rh agglutinins

Betacoronavirus Vaccines against COVID-19, MERS, and SARS

V(H)H (nanobody) directed against human glycophorin A: 764 a tool for autologous red cell agglutination assays

Infectious Diseases Society of America Guidelines on the Diagnosis of 768 COVID-19:Serologic Testing

The Agglutination of Red Cells by Allantoic Fluid of Chick Embryos Infected 770 with Influenza Virus

Plasmablast-derived antibody response 773 to acute SARS-CoV-2 infection in humans

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block 776 interaction with ACE2

Crystal structure of the 2019-nCoV spike receptor-binding domain bound with 783 the ACE2 receptor

On agglutination of normal human blood. Transfusion

Structure of SARS coronavirus spike receptor-787 binding domain complexed with receptor

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

Robin Coombs: his life and contribution to 793 haematology and transfusion medicine

Broad and strong 796 memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent 797 individuals following COVID-19

Mapping neutralizing 800 and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by 801 multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces 813 potent neutralising antibody responses

Human monoclonal antibody combination against SARS 816 coronavirus: synergy and coverage of escape mutants

The National SARS-CoV-2 Serology Assay Evaluation Group, The National SARS-CoV-2

Manuscript preprint: Head-to-head 820 benchmark evaluation of the sensitivity and specificity of five immunoassays for SARS

CoV-2 serology on >1500 samples

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle 824 vaccines for SARS-CoV-2. bioRxiv

Structural and 826 Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

A Simple Hemagglutination System Requiring Small 829 Amounts of Red Cells and Antibodies

Structural Basis for Potent Neutralization of Betacoronaviruses

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a 845 convalescent patient

One divalent nanobody VHH72-Fc and two monoclonal 851 antibodies FD-5D and EZ-7A specific for the RBD failed to agglutinate red cells with the IH4-852 RBD reagent. Three monoclonal antibodies to other regions of the spike protein EW-8B

Competing Interests none.